Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd has published a newspaper notice confirming the dispatch of the 31st Annual General Meeting notice and the annual report for FY 2025-2026 in 'Business Standard' and 'Makkal Kural' on August 20, 2026.

Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd announces its 31st Annual General Meeting (AGM) to be held on September 11, 2026, through video conferencing. The company has enclosed the Notice of the AGM and the Annual Report for the financial year 2025-2026, as per Regulation 34(1) of the SEBI (LODR) Regulations, 2015. The Annual Report highlights the company's progress in expansion plans, credit resilience, and corporate recognition, with a strong product pipeline, effective capacity utilization, and strong marketing strategies.

Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd has announced its Annual Report for the financial year 2025-2026, with a 167% growth in net profit to ₹111.00 million and a 3.26% growth in operating revenue to ₹1,506 million. The company has also received a credit rating upgrade from ICRA and has been recognized as the Emerging Company of the Year in Healthcare.

Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd published its unaudited financial results for the quarter ended June 30, 2026, in the newspapers 'Business Standard' and 'Makkal Kural' on August 13, 2026.

Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹2,658.32 lakhs and profit before tax at ₹7.51 lakhs.

Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹2,658.32 lakhs and profit for the period at ₹7.51 lakhs.

Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on August 11, 2026, to consider and approve the Un-Audited Financial Results for the Quarter ended June 30, 2026. The trading window for dealing in the shares by the Designated Persons of the Company and their immediate relatives remains closed from July 1, 2026, to August 13, 2026.

Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd announced the retirement of Mr. Navin Kumar, an Independent Director, upon completing his first term effective June 22, 2026. Consequently, he will also cease to be the Chairman of the Audit Committee and the Nomination & Remuneration Committee. The company has reconstituted these committees to ensure continued compliance with regulatory requirements, affirming that the board composition remains compliant.

Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd announced the routine retirement of Mr. Navin Kumar, an Independent Director, upon the completion of his first term, effective June 22, 2026. As a result, he will also cease to be the Chairman of the Audit Committee and the Nomination & Remuneration Committee. The company has subsequently reconstituted these committees, stating that the composition of the Board and its committees remains compliant with applicable regulations.